8-K current report · filed Oct 28, 2026

ENANTA PHARMACEUTICALS INC (ENTA) 8-K Current Report: October 28, 2026

Item 5.02Item 7.01Item EX-99.1ENTA overview

Short answer

ENANTA PHARMACEUTICALS INC (ENTA) filed an 8-K current report with the SEC on October 28, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). CEO Jay R. Luly, age 70, plans retirement by February 1, 2027 after 23 years leading Enanta.

ENANTA PHARMACEUTICALS INC 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • CEO Jay R. Luly, age 70, plans retirement by February 1, 2027 after 23 years leading Enanta
  • Expected 2027 strategic-advisor role could support leadership transition continuity
  • Board launched comprehensive internal and external search for successor, creating near-term succession uncertainty
  • Tara L. Kieffer, age 48, appointed to newly created Chief Operating Officer role
  • COO appointment includes no material employment agreement, related-party transaction, or family relationship disclosed

Item 7.01 · Regulation FD Disclosure

  • CEO Jay R. Luly, Ph.D. planned retirement, creating leadership-transition risk
  • Tara L. Kieffer, Ph.D. appointed Chief Operating Officer, effective succession step
  • Kieffer joined Enanta in 2020 and previously served as Chief Product Strategy Officer
  • Newly created COO role signals increased focus on operational execution and product strategy

Item EX-99.1 · Exhibit EX-99.1

  • CEO Jay R. Luly retiring by February 1, 2027 after 23 years leading Enanta
  • Luly remains Strategic Advisor through 2027, supporting leadership continuity
  • Board launched internal and external search for successor, creating execution and strategic-transition uncertainty
  • Tara L. Kieffer appointed Chief Operating Officer, strengthening operational focus across pipeline programs
  • Leadership transition arrives as Enanta advances RSV and immunology programs funded partly by AbbVie HCV royalties

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other ENANTA PHARMACEUTICALS INC 8-K filings

Get the next ENTA 8-K as it lands

Follow ENTA for push alerts, or ask the research agent what this filing means.